DISIPAL
LOE Approachingorphenadrine hydrochloride
NDAORALTABLET
Approved
May 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DISIPAL (orphenadrine hydrochloride) is an oral anticholinergic agent approved in 1957 for symptomatic relief of muscle spasm and related conditions. It functions as a central-acting muscle relaxant with anticholinergic properties. The drug is indicated for patients requiring adjunctive treatment of acute musculoskeletal disorders.
LOE Approaching
As LOE approaches with moderate competitive pressure (30%), brand team focus is shifting toward defensive strategies and retention initiatives rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career roles on DISIPAL are limited and increasingly defensive in nature, focused on maintaining market share and managing the LOE transition. Professionals considering this product should expect stable but non-growth-oriented responsibilities with emphasis on generic mitigation and compliance.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.